XOMA Royalty Corporation announced the completion of its acquisition of Turnstone Biologics Corp. on August 11, 2025. The transaction was finalized following a successful tender offer in which XOMA purchased all outstanding shares of Turnstone's common stock. Each share was acquired for $0.34 in cash and a contingent value right $(CVR)$ offering potential future payments. Post-transaction, Turnstone has become a wholly owned subsidiary of XOMA, continuing its operations under the new ownership structure.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-181840), on August 15, 2025, and is solely responsible for the information contained therein.